Nycomed Imaging As

Photocure Asa

Amersham Health As

Nycomed Salutar, Inc.

Nycomed As

Ge Healthcare As

Universitetet I Oslo

Other

Lauras As

Daiichi Pharmaceutical Co., Ltd.

Pci Biotech As

Natural Asa

Aker Biomarine Asa

Nycomed Innovation Ab

Natural Corporation

Jo Klaveness

Per Strande

Arne Berg

Pal Rongved

Harald Dugstad

Pangl Rongved

Torsten Almen

Lars Stubberud

Aslak Godal

P&aring;l Rongved

Alan Cuthbertson

Scott M Rocklage

Klaes Golman

Anne Naevestad

Roald Skurtveit

Thorfinn Ege

Michael Droege

Unni Nordby Wiggen

Helge Tolleshaug

Magne Solbakken

Keith Redford

Lars Hoff

Edward R Bacon

John L Toner

Ib Leunbach

Alan D Watson

Pål Rongved

Hanno Priebe

Halldis Hellebust

Gregory L McIntire

Asgeir Saebo

Paul Mark Henrichs

Hiroshi Kikuchi

Jan Remmereit

Morten Eriksen

Jere D Fellmann

Gene Curtis Jamieson

Kjell Undheim

Nils Olav Nilsen

Klaus D Krautwurst

Jan Solberg

Jon Erik Braenden

Sook-Hui Kim

Vinay Chandrakant Desai

Edvin Wilhelm Johannesen

Goran Pettersson

Kjetil Tasken

Anders H&oslash;gset

Peter Leander

Anne N&aelig;vestad

Dagfinn L&oslash;vhaug

Terje Thomassen

Per Antonius Foss

Helge G Gundersen

Wolfgang Hans Heinrich Gunther

Trond Jacobsen

Jere D Fellman

Kjetil Taskén

Clas Magne Kjølberg

Hans Christian Wulf

Klaus Bryn

Birgitte Lygren

Bjorn Fuglass

Ellen Ostensen

Shi-bao Yu

Brent Segal

Torsten Alm En

Egil Jellum

Bjørn Jarl Fagerlund

Johan E Moan

Sigmund Frigstad

Anne Kjersti Fahlvik

Qian Peng

Trond Warloe

Harald Steen

Karl E Gierskcky

Alf Bjorseth

John Varadarajan

Anders Hogset

Audun Tornes

Frode Rise

Richard J Himmelsbach

Kiyoto Yachi

Wolfgang H Gunther

Mahmood Amiry-Moghaddam

Jorunn Undheim Braenden

Pål Aukrust

Julian Cockbain

Finn Olav Levy

Jan Wadstein

Anne Jacobsen

Balin Balinov

Jon Erik Brænden

Einar Martin Aandahl

Stig S Frøland

Vidar Hansson

Oyvind Jacobsen

Ole Petter Ottersen

Bjorn Fuglaas

The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein Ato Aand Rto Rare as defined herein. Such compounds are suitable for use in the treatment or prevention of diseases or conditions which are mediated by the activation of lactate dehydrogenase A (LDHA), for example cancer. 

LDHA activity inhibitors

The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: Preferably, side effects of PDT are prevented or reduced by using (ii) or (iv) in combination with (i) and/or (ii).

Use of aminolevulinic acid and derivatives thereof

The present invention relates to tertiary amines of formula (I) for use in therapy, particularly for use in treating cardiovascular disorders. The compounds have been found to regulate phospholamban phosphorylation by interfering with the A-kinase anchor protein 18delta (AKAP18&#x3b4;) binding to the PKA substrate phospholamban. The compounds share a tri(alkylaryl/alkylheteroaryl) amine structure.

Tertiary amines for use in the treatment of cardiac disorders

Cyclic amino compounds for use in the treatment of cardiac disorders

The present invention relates to tertiary amines of formula (I) for use in therapy, particularly for use in treating cardiovascular disorders. The compounds have been found to regulate phospholamban phosphorylation by interfering with the A-kinase anchor protein 18delta (AKAP185) binding to the PKA substrate phospholamban. The compounds share a tri(alkylaryl/alkylheteroaryl)amine structure. 

The invention relates to new derivatives of 5-aminolevulinic acid (5-ALA) and their use as photosensitizing agents. In particular, it relates to compounds of general formula I and their pharmaceutically acceptable salts, to methods for preparing such compounds and their medical and cosmetic use, for example in methods of photodynamic therapy and diagnosis: whereinRrepresents a hydrogen atom or an optionally substituted alkyl or cycloalkyl group;R, each of which may be the same or different, represents a hydrogen atom or an optionally substituted alkyl group; andX is a linking group.

Carboxylic acid ALA esters

A peptide which can adopt a 3-helical conformation in which the side chains of two amino acid residues in the peptide backbone are linked by a group comprising an aromatic 5-membered ring.

Peptides

The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound.

Strontium compound for treatment of sub-dermal soft tissue pain

The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative. Due to their increased water solubility, such salts are particularly suitable for use in the preparation of parenteral pharmaceutical preparations, e.g. for use as solutions for injection or infusion.

Photosensitizing compositions

The invention provides the use of a photosensitizer which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitizer; and (b) photoactivating said photosensitizer, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitizer in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm(e.g. 5 to 40 mW/cm), (iv) said photoactivation is carried out with sunlight. Preferably, side-effects of PDT are prevented or reduced by using (iii) or (iv) in combination with (i) and/or (ii).

A peptide comprising a unit of formula (I) and having a molecular weight of less than 2000 wherein each X is independently an organic group, e.g. a Calkyl or Calkenyl group, preferably &#x2014;CH&#x2014;CH&#x2550;CH, or the two X groups taken together can form a covalent or non-covalent link between the two O groups, preferably a Csaturated or unsaturated carbon chain optionally interrupted by one or more heteroatoms selected from O, S, N, P, or Si, especially a Ccarbon chain or one X represents an azido group and the other an C2-6-alkynyl group; both Z's are the same and are O or S; each Y is independently C, CH, CH, N or NH; Ris H or Calkyl; Ris H or Calkyl; Ris a Calkyl group, preferably isopropyl; or a salt, ester or prodrug thereof. 

Compounds, compositions and use

The present invention provides an acid addition salt of 5-aminolevulinic acid (5-ALA) or of a 5-ALA derivative (e.g. a 5-ALA ester) with an acid which has a pKa of about 5 or less, preferably about 3 or less, with the proviso that the acid is other than hydrochloric acid. Particularly preferred salts are those derived from acids selected from the group comprising sulphonic acid and its derivatives, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid. The salts in accordance with the invention are particularly suitable for use as photosensitizing agents in diagnosis and photochemotherapy of disorders or abnormalities of external or internal surfaces of the body.

Acid addition salts of 5-aminolevulinic acid or its derivatives

The invention provides use of a photosensitiser, which is a derivative (e.g., an ester) of 5-aminolevulinic acid (5-ALA) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention or treatment of acne.

Treatment of acne using derivatives of 5-aminolevulinic acid

The present invention provides a method of treatment of a human or non-human (e.g. mammalian, avian or reptilian) animal subject by the parenteral administration of a lipophilic pharmaceutical agent, the improvement comprising administering said pharmaceutical agent in an oil-in-water emulsion containing a conjugated linoleic acid or a physiologically tolerable derivative thereof.

Compositions comprising an o/w emulsion containing conjugated linoleic acid

This invention provides novel 8-carbyl substituted cAMPS and a novel procedures for the preparation of 8-Br-cAMP, a key starting material.

Purine nucleotide derivatives

Growing community of inventors

Oslo, Norway

Jo Klaveness